These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3121116)

  • 21. [A single infusion of Pamidronate (APD) in Paget's disease of bone].
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1989 Jan; 119(3):71-4. PubMed ID: 2711157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paget's disease of bone: current concepts in pathogenesis and treatment.
    Thomas DW; Shepherd JP
    J Oral Pathol Med; 1994 Jan; 23(1):12-6. PubMed ID: 8138975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pamidronate on indices of bone turnover in Paget's disease followed for 6 years.
    Worsfold M; Sharp CA; Rowlands PR; Davie MW
    Semin Arthritis Rheum; 1994 Feb; 23(4):285. PubMed ID: 8009262
    [No Abstract]   [Full Text] [Related]  

  • 24. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
    Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
    J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of remission of Paget's disease of bone.
    Patel S; Stone MD; Coupland C; Hosking DJ
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three phase 99Tcm (V)DMSA scintigraphy in Paget's disease: an indicator of pamidronate effect.
    Kobayashi H; Shigeno C; Sakahara H; Yamamoto T; Hosono M; Fujimoto R; Konishi J
    Br J Radiol; 1997 Oct; 70(838):1056-9. PubMed ID: 9404211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone.
    Buckler HM; Mercer SJ; Davison CE; Hollis S; Richardson PC; Anderson DG
    Ann Rheum Dis; 1998 Sep; 57(9):572. PubMed ID: 9849319
    [No Abstract]   [Full Text] [Related]  

  • 28. Single-dose intravenous pamidronate is effective alternative therapy for Paget's disease refractory to calcitonin.
    Yap AS; Mortimer RH; Jacobi JM; Galligan JP; Perry-Keene DA; Khafagi FA
    Horm Res; 1991; 36(1-2):70-4. PubMed ID: 1814803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralisation defects after pamidronate for Paget's disease.
    Boyce BF; Adamson BB; Gallacher SJ; Byars J; Ralston SH; Boyle IT
    Lancet; 1994 May; 343(8907):1231-2. PubMed ID: 7909901
    [No Abstract]   [Full Text] [Related]  

  • 30. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
    Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
    Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Paget's disease of bone with single-dose intravenous pamidronate.
    Watts RA; Skingle S; Bhambani M; Pountain G; Crisp AJ
    Semin Arthritis Rheum; 1994 Feb; 23(4):281. PubMed ID: 8009259
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE
    Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
    Wilczek H
    Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Paget's disease of bone.
    Anderson D; Cantrill JC
    Br Med J (Clin Res Ed); 1988 Jan; 296(6617):291. PubMed ID: 3124919
    [No Abstract]   [Full Text] [Related]  

  • 35. Paget's disease with osteolytic lesions: combining medical and surgical treatments.
    Brumsen C; Bloem RM; Papapoulos SE
    Neth J Med; 1992 Jun; 40(5-6):292-8. PubMed ID: 1436268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moderate Paget's disease treated with pamidronate: comparison of various infusion rates for a 60-mg single dose.
    Thiebaud D; Portmann L; Burckhardt P
    Semin Arthritis Rheum; 1994 Feb; 23(4):279. PubMed ID: 8009257
    [No Abstract]   [Full Text] [Related]  

  • 37. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
    Drake S; Massie JD; Postlethwaite AE; Palmieri GM
    Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
    Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
    J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paget's disease: ocular complications of disodium pamidronate treatment.
    O'Donnell NP; Rao GP; Aguis-Fernandez A
    Br J Clin Pract; 1995; 49(5):272-3. PubMed ID: 7492469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.